(Q39636226)

13 September 2017

title

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent (English)

1 reference

13 September 2017

0 references

1 reference

1 reference

Matthew Burge

1

1 reference

13 September 2017

Alessandra B Francesconi

2

1 reference

13 September 2017

Dusan Kotasek

3

1 reference

13 September 2017

Rosa Fida

4

1 reference

13 September 2017

Gregg Smith

5

1 reference

13 September 2017

Andrew Wilks

6

1 reference

13 September 2017

Paul A Vasey

7

1 reference

13 September 2017

Jason D Lickliter

8

1 reference

13 September 2017

language of work or name

1 reference

27 March 2012

1 reference

Investigational New Drugs

13 September 2017

published in

1 reference

13 September 2017

volume

31

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

126-135

1 reference

Role of angiogenesis in tumor growth and metastasis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9813-Y

Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22451157

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Accelerated titration designs for phase I clinical trials in oncology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22451157

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-012-9813-Y

1 reference

13 September 2017

1 reference